PharmaNet Development Group announced that its subsidiary, PharmaNet Canada, Inc. (PharmaNet) and Maisonneuve-Rosemont Hospital (HMR) and its Research Center have agreed to collaborate in the conduct of pharmacokinetic studies in patientswith impaired renal function.
At PharmaNet's clinical pharmacology unit in Canada, new drugs are evaluated in Phase I clinical studies for PharmaNet's clients. Under the current FDA draft guidance, certain of these studies require the evaluation of drug products in study participants that have impaired renal function. The collaboration with HMR will provide PharmaNet enhanced access to potential study participants with mild, moderate, or severe impaired renal function.
"We are very pleased to partner with HMR," commented Riaz Bandali, President, Early Stage Development. "Demand for the conduct of pharmacokinetic studies in patients with impaired renal function is increasing. By partnering with HMR we can efficiently conduct trials in patients with various levels of renal impairment, while assuring the patients' safety and well-being."
Mr. Bandali added, "We view this partnership with HMR as an important first step in PharmaNet's strategy to expand our academic expertise and the number of first-in-person and patient studies that we conduct in hospital settings."
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.